MedTrace Logo

Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above

NCT04526990 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44247

Last updated 2023-06-15

No results posted yet for this study

Summary

This study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above.

Conditions

Interventions

BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intramuscular administration

BIOLOGICAL

Placebo

Intramuscular administration

Sponsors & Collaborators

  • Beijing Institute of Biotechnology

    collaborator OTHER

  • CanSino Biologics Inc.

    lead INDUSTRY

Principal Investigators

  • Scott A Halperin, MD · Canadian Center for Vaccinology

  • Fengcai Zhu · Jiangsu Provincial Center for Disease Control and Prevention

  • Joanne M angley, MD · Canadian Center for Vaccinology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2021-08-07
Completion
2022-10-21

Countries

  • Argentina
  • Chile
  • Mexico
  • Pakistan
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04526990 on ClinicalTrials.gov